Momelotinib reduces transfusion requirements in patients with myelofibrosis

Affiliations

• ¹ Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, USA.
• ² Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
• ³ Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
• ⁴ Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ⁵ Haematology Department, Monash University & Frankston Hospital, Frankston, Australia.
• ⁶ Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
• ⁷ Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.
• ⁸ Hematooncology Department, Medical University of Lublin, Lublin, Poland.
• ⁹ Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, Paris, France.
• ¹⁰ Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
• ¹¹ Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ¹² Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA.
• ¹³ Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany.
• ¹⁴ Department of Hematology, Medical University of Lodz, Lodz, Poland.
• ¹⁵ Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
• ¹⁶ Biometrics, Sierra Oncology Inc, San Mateo, CA, USA.
• ¹⁷ Biostatistics, International Drug Development Institute, Louvain-la-Neuve, Belgium.
• ¹⁸ Research and Early Development, Sierra Oncology Inc, San Mateo, CA, USA.
• ¹⁹ Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.